Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 5/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 5/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 6/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7609766 | 1.00 | SRD5A1 (0.51) | SRD5A1CYP2C19SRD5A2CYP19A1 | |
| SCHEMBL7616969 | 0.84 | SRD5A1 (0.51) | SRD5A1CYP2C19SRD5A2CYP19A1 | |
| SCHEMBL7616961 | 0.84 | SRD5A1 (0.51) | SRD5A1CYP2C19SRD5A2CYP19A1 | |
| SCHEMBL7609134 | 0.78 | SRD5A1 (0.54) | SRD5A1CYP2C19SRD5A2CYP19A1 | |
| SCHEMBL7609129 | 0.78 | SRD5A1 (0.54) | SRD5A1CYP2C19SRD5A2CYP19A1 | |
| SCHEMBL7713753 | 0.76 | SRD5A1 (0.49) | SRD5A1SRD5A2 | |
| SCHEMBL7713756 | 0.76 | SRD5A1 (0.49) | SRD5A1SRD5A2 | |
| SCHEMBL7611353 | 0.76 | SRD5A1 (0.52) | SRD5A1CYP2C19SRD5A2 | |
| SCHEMBL8065397 | 0.73 | SRD5A1 (0.60) | SRD5A1CYP2C19SRD5A2CYP19A1 | |
| SCHEMBL8065395 | 0.73 | SRD5A1 (0.60) | SRD5A1CYP2C19SRD5A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0880540-B1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | AVENTIS PHARMA INC (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6365597-B1 | FOR THERAPY OF ANDROGEN AND ESTROGEN MEDIATED DISORDERS, INCLUDING BENIGN PROSTATIC HYPERPLASIA, ANDROGEN MEDIATED PROSTATE CANCER, ESTROGEN MEDIATED BREAST CANCER AND ACNE | AVENTIS PHARMACEUTICALS INC. | 2002-04-02 | — | — | US | disclosed |
| EP-0880540-A1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | HOECHST MARION ROUSSEL, INC. (US) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997030069-A1 | 17-BETA-CYCLOPROPYL(AMINO/OXY) 4-AZA STEROIDS AS ACTIVE INHIBITORS OF TESTOSTERONE 5-ALPHA-REDUCTASE AND C17-20-LYASE | HOECHST MARION ROUSSEL, INC. (US) | 1997-08-21 | — | — | WO | disclosed |